#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	17994	16S	1529	1529	99.87	16S.l6.c17.ctg.1	2453	904.6	0	.	n	.	0	C326T	SNP	326	326	C	769	769	T	1066	T,C,G,A	553,509,3,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	17994	16S	1529	1529	99.87	16S.l6.c17.ctg.1	2453	904.6	0	.	n	.	0	C1450T	SNP	1450	1450	C	1893	1893	T	1143	T,G,A	1141,1,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	17994	16S	1529	1529	99.87	16S.l6.c17.ctg.1	2453	904.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1627	1627	C	1178	C,A,G	1175,2,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30616	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3963	962.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1865	1865	A	1331	A,G,T	1328,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30616	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3963	962.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2499	2499	C	1034	C,A,T,G	1030,2,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30616	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3963	962.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2573	2573	A	969	A	969	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30616	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3963	962.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	3125	3125	C	1059	C,A	1057,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_N_01367c	folP.WHO_N_01367c	1	1	27	2456	folP	852	852	100.0	folP.l15.c4.ctg.1	2081	147.2	1	SNP	p	R228S	1	.	.	682	684	AGC	1273	1275	AGC	229;230;231	A;G,C;C	229;229,1;231	folP.WHO_N_01367c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6116	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3830	199.1	1	SNP	p	S91F	0	.	.	271	273	TCC	813	815	TCC	239;242;244	T;C;C	239;242;244	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6116	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3830	199.1	1	SNP	p	D95N	0	.	.	283	285	GAC	825	827	GAC	242;243;243	G;A;C	242;243;243	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6116	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3830	199.1	1	SNP	p	D95G	0	.	.	283	285	GAC	825	827	GAC	242;243;243	G;A;C	242;243;243	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	2152	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1827	147.1	0	.	p	.	0	A39T	NONSYN	115	117	GCC	686	688	ACC	224;224;221	A;C;C	224;224;221	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	2152	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1827	147.1	0	.	p	.	0	R44H	NONSYN	130	132	CGC	701	703	CAC	213;216;216	C;A;C	213;216;216	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	2152	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1827	147.1	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	884	886	CAC	288;289;288	C;A;C	288;289;288	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	2152	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1827	147.1	1	SNP	p	G45D	0	.	.	133	135	GGC	704	706	GGC	219;218;220	G,C,T;G,A;C	217,1,1;217,1;220	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1368	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1409	121.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	6516	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3520	230.8	0	.	p	.	0	V384I	NONSYN	1150	1152	GTC	1775	1777	ATC	323;324;324	A;T;C,A	323;324;323,1	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	6516	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3520	230.8	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1928	1930	GCA	338;338;338	G;C;A	338;338;338	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	6516	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3520	230.8	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2411	2413	ATT	336;335;334	A;T,C;T	336;334,1;334	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	6516	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3520	230.8	1	SNP	p	D86N	0	.	.	256	258	GAC	881	883	GAC	299;298;294	G,T;A,C;C,A	298,1;297,1;293,1	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	6516	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3520	230.8	1	SNP	p	S87I	0	.	.	259	261	AGT	884	886	AGT	294;295;293	A,G,C;G,T;T	292,1,1;294,1;293	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	6516	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3520	230.8	1	SNP	p	S87W	0	.	.	259	261	AGT	884	886	AGT	294;295;293	A,G,C;G,T;T	292,1,1;294,1;293	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	6516	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3520	230.8	1	SNP	p	S87R	0	.	.	259	261	AGT	884	886	AGT	294;295;293	A,G,C;G,T;T	292,1,1;294,1;293	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	6516	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3520	230.8	1	SNP	p	S88P	0	.	.	262	264	TCC	887	889	TCC	293;291;292	T,G,C,A;C,T;C,A	290,1,1,1;290,1;290,2	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4838	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3067	196.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1752	1754	GGC	228;225;225	G;G,A;C,A	228;224,1;224,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.15.001	penA.15.001	1	1	27	4676	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2713	214.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1453	1455	GCA	295;293;292	G;C,T;A,C	295;292,1;291,1	penA.15.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4676	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2713	214.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1456	1458	ATC	293;294;294	A;T,G;C,A	293;293,1;293,1	penA.15.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4676	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2713	214.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1468	1470	GTG	289;286;285	G,T;T;G,T	288,1;286;283,2	penA.15.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4676	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2713	214.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1468	1470	GTG	289;286;285	G,T;T;G,T	288,1;286;283,2	penA.15.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4676	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2713	214.4	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1969	1971	ACC	283;280;281	A,T,G,C;C;C	280,1,1,1;280;281	penA.15.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4676	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2713	214.4	1	SNP	p	A501V	0	.	.	1501	1503	GCG	2023	2025	GCG	253;254;253	G,T;C,G;G,T	252,1;253,1;252,1	penA.15.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4676	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2713	214.4	1	SNP	p	A501P	0	.	.	1501	1503	GCG	2023	2025	GCG	253;254;253	G,T;C,G;G,T	252,1;253,1;252,1	penA.15.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4676	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2713	214.4	1	SNP	p	G542S	0	.	.	1624	1626	GGC	2146	2148	GGC	264;267;272	G,T,C;G,T;C,T	262,1,1;266,1;271,1	penA.15.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4676	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2713	214.4	1	SNP	p	G545S	0	.	.	1633	1635	GGC	2155	2157	GGC	269;273;274	G;G;C	269;272;274	penA.15.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4676	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2713	214.4	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2173	2175	CCG	274;272;270	C,G,A;C;G	271,2,1;272;270	penA.15.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6960	ponA	2397	2397	99.96	ponA.l6.c30.ctg.1	3641	238.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2758	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2257	152.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	746	746	C	228	C,A	227,1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	314	porB1a	984	269	90.84	porB1a.l15.c30.ctg.1	1021	30.8	0	.	p	.	0	H217N	NONSYN	649	651	CAT	777	779	AAT	4;4;4	A;A;T	4;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	314	porB1a	984	269	90.84	porB1a.l15.c30.ctg.1	1021	30.8	0	.	p	.	0	D218N	NONSYN	652	654	GAT	780	782	AAT	4;4;4	A;A;T	4;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	314	porB1a	984	269	90.84	porB1a.l15.c30.ctg.1	1021	30.8	0	.	p	.	0	A222V	NONSYN	664	666	GCT	792	794	GTT	5;5;5	G;T;T	5;5;5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	314	porB1a	984	269	90.84	porB1a.l15.c30.ctg.1	1021	30.8	0	.	p	.	0	V226A	NONSYN	676	678	GTA	804	806	GCA	5;5;5	G;C;A	5;5;5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	314	porB1a	984	269	90.84	porB1a.l15.c30.ctg.1	1021	30.8	0	.	p	.	0	.	MULTIPLE	700	702	ACT	827	829	GTA	5;5;4	G;T;A	5;5;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	314	porB1a	984	269	90.84	porB1a.l15.c30.ctg.1	1021	30.8	0	.	p	.	0	D238fs	FSHIFT	712	712	G	839	839	G	4	G	4	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3376	porB1b	1035	1035	96.1	porB1b.l15.c17.ctg.1	1702	244.6	0	.	p	.	0	R40Q	NONSYN	118	120	CGG	541	543	CAG	295;300;300	C;A,C;G	295;299,1;300	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3376	porB1b	1035	1035	96.1	porB1b.l15.c17.ctg.1	1702	244.6	0	.	p	.	0	E48G	NONSYN	142	144	GAA	565	567	GGA	314;317;318	G,T;G;A,T,C	313,1;317;316,1,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3376	porB1b	1035	1035	96.1	porB1b.l15.c17.ctg.1	1702	244.6	0	.	p	.	0	F135L	NONSYN	403	405	TTT	826	828	CTT	276;274;278	C;T,G;T,G	276;273,1;277,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3376	porB1b	1035	1035	96.1	porB1b.l15.c17.ctg.1	1702	244.6	0	.	p	.	0	R143G	NONSYN	427	429	AGA	850	852	GGA	275;272;276	G;G,T,C;A	275;270,1,1;276	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3376	porB1b	1035	1035	96.1	porB1b.l15.c17.ctg.1	1702	244.6	0	.	p	.	0	G189S	NONSYN	565	567	GGC	988	990	AGC	292;293;293	A,C;G;C,T	291,1;293;292,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3376	porB1b	1035	1035	96.1	porB1b.l15.c17.ctg.1	1702	244.6	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1054	1054	T	327	T	327	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3376	porB1b	1035	1035	96.1	porB1b.l15.c17.ctg.1	1702	244.6	1	SNP	p	G120K	0	.	.	358	360	GGT	781	783	GGT	313;312;312	G;G,C;T,G	313;311,1;311,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3376	porB1b	1035	1035	96.1	porB1b.l15.c17.ctg.1	1702	244.6	1	SNP	p	A121N	0	.	.	361	363	GCC	784	786	GCC	313;313;313	G;C,T;C,G	313;312,1;312,1	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3376	porB1b	1035	1035	96.1	porB1b.l15.c17.ctg.1	1702	244.6	1	SNP	p	A121D	0	.	.	361	363	GCC	784	786	GCC	313;313;313	G;C,T;C,G	313;312,1;312,1	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	11986	rpoB	4179	4179	99.98	rpoB.l6.c17.ctg.1	5223	286.2	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2219	2221	CAT	311;312;312	C;A;T	311;312;312	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	1734	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1397	154.0	1	SNP	p	V57M	0	.	.	169	171	GTG	796	798	GTG	302;304;303	G;T;G	302;304;303	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
